Biocon Pharma gets USFDA nod for vital gut, liver drug
Biocon Pharma just got a tentative go-ahead from the USFDA for its 550mg Rifaximin Tablets, teaming up with Carnegie Pharmaceuticals LLC.
This means Biocon can soon bring a generic version of this antibacterial drug to the US market.
Rifaximin treats tough conditions; Biocon can now offer affordable options
Rifaximin helps adults manage irritable bowel syndrome with diarrhea (IBS-D) and lowers the risk of recurring hepatic encephalopathy—a serious liver-related brain condition.
With this approval, Biocon is set to offer a more affordable option for these tough-to-treat conditions.
The market took it in stride, with Biocon shares holding steady at around ₹347.
This is a big win for Biocon Pharma
This is a big win for Biocon Pharma, showing they're making real moves in the US generics space and building strong partnerships.
More importantly, it means better access to crucial meds for people dealing with serious gut and liver issues—without breaking the bank.